Boosted protease inhibitor monotherapy in HIV-infected adults: outputs from a pan-European expert panel meeting
Authors:
- José R ArribasJAJosé R Arribas
- Manuela DoroanaMDManuela Doroana
- Dan TurnerDTDan Turner
- Linos VandekerckhoveLVLinos Vandekerckhove
- Adrian Streinu-CercelASAdrian Streinu-Cercel
- On Behalf Of The Panel MembersOMOn Behalf Of The Panel Members
Open Access
- 1 January 2013
- journal article
- review article
- Published by Springer Nature in AIDS Research and Therapy
- Vol. 10 (1) , 1-9
Abstract
While the introduction of combination highly active antiretroviral therapy (HAART) regimens represents an important advance in the management of human immunodeficiency virus (HIV)-infected patients, tolerability can be an issue and the use of several different agents may produce problems. The switch of combination HAART to ritonavir-boosted protease inhibitor (PI) monotherapy may offer the opportunity to maintain antiviral efficacy while reducing treatment complexity and the risks of toxicity. Current European AIDS Clinical Society (EACS) guidelines recognise ritonavir-boosted PI monotherapy with twice-daily lopinavir/ritonavir or once-daily darunavir/ritonavir as a possible option in patients who have intolerance to nucleoside reverse transcriptase inhibitors, or for treatment simplification. Clinical trials data for PI boosted monotherapy are encouraging, showing substantial efficacy in the majority of patients; however, further data are required before this approach can be recommended as a routine treatment. Available data indicate that the most suitable candidates for the use of boosted PI monotherapy are long-term virologically suppressed patients who have demonstrated good adherence to antiretroviral therapy, who do not have chronic hepatitis B, have no history of treatment failure on PIs and are able to tolerate low-dose ritonavir.Keywords
This publication has 25 references indexed in Scilit:
- Switching to darunavir/ritonavir monotherapy vs. triple-therapy on body fat redistribution and bone mass in HIV-infected adults: the Monarch randomized controlled trialInternational Journal of STD & AIDS, 2013
- Documento de consenso de Gesida/Plan Nacional sobre el Sida respecto al tratamiento antirretroviral en adultos infectados por el virus de la inmunodeficiencia humana (actualización enero de 2012)Enfermedades Infecciosas y Microbiología Clínica, 2012
- The MONET trial: week 144 analysis of the efficacy of darunavir/ritonavir (DRV/r) monotherapy versus DRV/r plus two nucleoside reverse transcriptase inhibitors, for patients with viral load < 50 HIV‐1 RNA copies/mL at baselineHIV Medicine, 2012
- Factors Associated With Virological Failure in HIV-1–Infected Patients Receiving Darunavir/Ritonavir MonotherapyThe Journal of Infectious Diseases, 2011
- Effectiveness of Protease Inhibitor Monotherapy versus Combination Antiretroviral Maintenance Therapy: A Meta-AnalysisPLOS ONE, 2011
- Low Frequency of Intermittent HIV-1 Semen Excretion in Patients Treated with Darunavir-Ritonavir at 600/100 Milligrams Twice a Day plus Two Nucleoside Reverse Transcriptase Inhibitors or MonotherapyAntimicrobial Agents and Chemotherapy, 2010
- Efficacy of darunavir/ritonavir maintenance monotherapy in patients with HIV-1 viral suppression: a randomized open-label, noninferiority trial, MONOI-ANRS 136AIDS, 2010
- Randomized controlled study demonstrating failure of LPV/r monotherapy in HIV: the role of compartment and CD4-nadirAIDS, 2010
- Validation of the CNS Penetration-Effectiveness Rank for Quantifying Antiretroviral Penetration Into the Central Nervous SystemArchives of Neurology, 2008
- Class of Antiretroviral Drugs and the Risk of Myocardial InfarctionNew England Journal of Medicine, 2007